Hongmei Cui
University of Tennessee Health Science Center
Drug resistancemicroRNAVemurafenibLung cancerV600EPaclitaxelMelanomaImmunotherapyDrugOncogeneTargeted therapyATP-binding cassette transporterCancer researchMAPK/ERK pathwayMedicineProtein kinase BPI3K/AKT/mTOR pathwayCancer cell
Publications 2
#1Hongmei Cui (UTHSC: University of Tennessee Health Science Center)H-Index: 5
#2Qinghui WangH-Index: 9
Last. Wei LiH-Index: 54
view all 4 authors...
Melanoma is one of the deadliest skin cancers having a five-year survival rate around 15-20%. An overactivated MAPK/AKT pathway is well-established in BRAF mutant melanoma. Vemurafenib (Vem) was the first FDA-approved BRAF inhibitor and gained great clinical success in treating late-stage melanoma. However, most patients develop acquired resistance to Vem within 6-9 months. Therefore, developing a new treatment strategy to overcome Vem-resistance is highly significant. Our previous study reporte...
#1Hongmei Cui (UTHSC: University of Tennessee Health Science Center)H-Index: 5
#2Kinsie E. Arnst (UTHSC: University of Tennessee Health Science Center)H-Index: 7
view all 4 authors...
Paclitaxel (PTX) is a first-line drug for late-stage non-small cell lung cancer (NSCLC) patients who do not benefit from targeted therapy or immunotherapy. However, patients invariably develop resistance to PTX upon prolonged treatments. Although diverse mechanisms leading to PTX resistance have been well-documented in the literature, strategies to overcome PTX resistance in NSCLC based on these mechanisms are still challenging. In this article, we reviewed recent advancements elucidating major ...
5 CitationsSource